| pubmed-article:3156755 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3156755 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:3156755 | lifeskim:mentions | umls-concept:C0005821 | lld:lifeskim |
| pubmed-article:3156755 | lifeskim:mentions | umls-concept:C0034838 | lld:lifeskim |
| pubmed-article:3156755 | lifeskim:mentions | umls-concept:C0042523 | lld:lifeskim |
| pubmed-article:3156755 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:3156755 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3156755 | pubmed:dateCreated | 1985-5-15 | lld:pubmed |
| pubmed-article:3156755 | pubmed:abstractText | In human blood platelets verapamil and D600 (2-methoxyverapamil) in therapeutic concentrations inhibited the shape change reaction induced by 5-hydroxytryptamine (5HT) but not that induced by ADP. The N-methylated derivatives (D575 and D890) had much less effect. The inhibitory action of verapamil was independent of external Ca2+. Nitrendipine and diltiazem (20 microM) had no effect on the 5HT- and the ADP-induced shape change reactions. Since both these shape change reactions are mediated by a rise in cytoplasmic free Ca2+, it is concluded that the inhibition of the 5HT effect by verapamil and D600 was not due to their interference with calcium channels but rather to an antagonistic action on 5HT2-receptors. This view is supported by the finding that verapamil but not D575 competed with [3H]ketanserin and [3H]spiroperidol for their specific binding sites on membranes of rat cerebral cortex. | lld:pubmed |
| pubmed-article:3156755 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3156755 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3156755 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3156755 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:3156755 | pubmed:issn | 0014-2999 | lld:pubmed |
| pubmed-article:3156755 | pubmed:author | pubmed-author:PletscherAA | lld:pubmed |
| pubmed-article:3156755 | pubmed:author | pubmed-author:AffolterHH | lld:pubmed |
| pubmed-article:3156755 | pubmed:author | pubmed-author:BurkardW PWP | lld:pubmed |
| pubmed-article:3156755 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3156755 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:3156755 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:3156755 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3156755 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3156755 | pubmed:pagination | 157-62 | lld:pubmed |
| pubmed-article:3156755 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:meshHeading | pubmed-meshheading:3156755-... | lld:pubmed |
| pubmed-article:3156755 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3156755 | pubmed:articleTitle | Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets. | lld:pubmed |
| pubmed-article:3156755 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3156755 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:3156755 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3156755 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3156755 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3156755 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3156755 | lld:pubmed |
